中国临床药理学杂志2024，Vol.40Issue(4)：611-614,4.DOI:10.13699/j.cnki.1001-6821.2024.04.028
治疗更年期女性血管舒缩症状的新药Fezolinetant
Fezolinetant,a new approved drug for the treatment of vasomotor symptoms in menopausal women
卞婷婷 1何心2
作者信息
- 1. 扬州市妇幼保健院,扬州大学附属扬州妇幼保健院药学部,江苏扬州 225000
- 2. 南京医科大学附属妇产医院、南京市妇幼保健院药学部,江苏南京 210004
- 折叠
摘要
Abstract
Fezolinetant has been approved by the U.S.Food and Drug Administration(FDA)for the treatment of moderate/severe vasomotor symptoms(VMS)in menopausal women.The Fezolinetant tablet is for oral use and is a neurokinin 3 receptor(NK3R)antagonist that blocks neurokinin B binding on the KNDy neuron.Clinical studys indicate that Fezolinetant can reduce the frequency and severity of VMS and improve quality of life.The mechanism of action,pharmacodynamics,pharmacokinetics,clinical study and safety were introduced.关键词
Fezolinetant/血管舒缩症状/更年期妇女/非激素疗法Key words
Fezolinetant/vasomotor symptoms/menopausal women/non-hormone therapy分类
医药卫生引用本文复制引用
卞婷婷,何心..治疗更年期女性血管舒缩症状的新药Fezolinetant[J].中国临床药理学杂志,2024,40(4):611-614,4.
